WallStSmart

NVE Corporation (NVEC)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 898% more annual revenue ($258.90M vs $25.95M). NVEC leads profitability with a 54.6% profit margin vs -15.5%. NVEC earns a higher WallStSmart Score of 69/100 (B-).

NVEC

Strong Buy

69

out of 100

Grade: B-

Growth: 5.3Profit: 9.5Value: 5.3Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVECSignificantly Overvalued (-29.6%)

Margin of Safety

-29.6%

Fair Value

$52.16

Current Price

$82.79

$30.63 premium

UndervaluedFair: $52.16Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVEC5 strengths · Avg: 9.0/10
Profit MarginProfitability
54.6%10/10

Keeps 55 of every $100 in revenue as profit

Operating MarginProfitability
60.2%10/10

Strong operational efficiency at 60.2%

Return on EquityProfitability
23.4%9/10

Every $100 of equity generates 23 in profit

PEG RatioValuation
0.848/10

Growing faster than its price suggests

Revenue GrowthGrowth
22.9%8/10

Revenue surging 22.9% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

NVEC2 concerns · Avg: 3.5/10
P/E RatioValuation
27.7x4/10

Moderate valuation

Market CapQuality
$390.65M3/10

Smaller company, higher risk/reward

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : NVEC

The strongest argument for NVEC centers on Profit Margin, Operating Margin, Return on Equity. Profitability is solid with margins at 54.6% and operating margin at 60.2%. Revenue growth of 22.9% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : NVEC

The primary concerns for NVEC are P/E Ratio, Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

NVEC profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVEC scores higher overall (69/100 vs 41/100), backed by strong 54.6% margins and 22.9% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

NVE Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on the spin of the electron to acquire, store, and transmit information in the United States and internationally. The company is headquartered in Eden Prairie, Minnesota.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?